Boston Scientific (BSX) EVP exercises stock options, sells 17,313 shares

Rhea-AI Filing Summary

Boston Scientific executive reports option exercises and share sale. An officer of Boston Scientific Corp. exercised multiple stock options on 12/01/2025, acquiring 17,313 shares of common stock at exercise prices ranging from $17.26 to $27.09 per share. On the same date, the executive sold 17,313 shares of common stock in an open-market transaction at a weighted average price of $101.5531 per share under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. After these transactions, the executive directly held 23,600 shares of Boston Scientific common stock and indirectly held 13,354 shares through the company’s 401(k) Retirement Savings Plan.

Insider Trade Summary

Net Seller: 17,313 shares ($1,758,189)

Net Sell 10 txns

Insider Butcher Arthur C

Role EVP& Grp Pres, MedSurg & APAC

Sold 17,313 shs ($1.76M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,952	$0.00	--
Exercise	Stock Option (Right to Buy)	1,009	$0.00	--
Exercise	Stock Option (Right to Buy)	6,175	$0.00	--
Exercise	Stock Option (Right to Buy)	3,177	$0.00	--
Exercise	Common Stock	6,952	$27.09	$188K
Exercise	Common Stock	6,175	$24.55	$152K
Exercise	Common Stock	3,177	$22.71	$72K
Exercise	Common Stock	1,009	$17.26	$17K
Sale	Common Stock	17,313	$101.5531	$1.76M
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 30,552 shares (Direct); Common Stock — 13,354 shares (Indirect, By 401(k))

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $101.11 to $101.89, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Butcher Arthur C

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP& Grp Pres, MedSurg & APAC

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		M(1)		6,952	A	$27.09	30,552	D
Common Stock	12/01/2025		M(1)		6,175	A	$24.55	36,727	D
Common Stock	12/01/2025		M(1)		3,177	A	$22.71	39,904	D
Common Stock	12/01/2025		M(1)		1,009	A	$17.26	40,913	D
Common Stock	12/01/2025		S(1)		17,313	D	$101.5531(2)	23,600	D
Common Stock								13,354(3)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.09	12/01/2025		M(1)			6,952	(4)	02/15/2028	Common Stock	6,952	$0.0000	0.0000	D
Stock Option (Right to Buy)	$17.26	12/01/2025		M(1)			1,009	(5)	02/22/2026	Common Stock	1,009	$0.0000	0.0000	D
Stock Option (Right to Buy)	$24.55	12/01/2025		M(1)			6,175	(6)	02/28/2027	Common Stock	6,175	$0.0000	0.0000	D
Stock Option (Right to Buy)	$22.71	12/01/2025		M(1)			3,177	(7)	06/01/2026	Common Stock	3,177	$0.0000	0.0000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $101.11 to $101.89, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

4. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

5. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

6. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

7. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Boston Scientific (BSX) report in this Form 4?

The Form 4 reports that a Boston Scientific executive exercised options to acquire 17,313 shares of common stock and sold 17,313 shares on 12/01/2025 in an open-market transaction.

Who is the reporting person in the Boston Scientific (BSX) Form 4 and what is their role?

The reporting person is an officer of Boston Scientific Corp. serving as EVP & Group President, MedSurg & APAC, as indicated in the relationship section.

At what prices were the Boston Scientific (BSX) stock options exercised and shares sold?

The executive exercised options with exercise prices of $17.26, $22.71, $24.55, and $27.09 per share, and sold 17,313 shares at a weighted average price of $101.5531 per share.

How many Boston Scientific (BSX) shares does the executive own after these transactions?

Following the reported transactions, the executive directly owned 23,600 shares of Boston Scientific common stock and indirectly owned 13,354 shares through the company’s 401(k) Retirement Savings Plan.

Were the Boston Scientific (BSX) insider sales made under a Rule 10b5-1 plan?

Yes. The explanation states that the transactions were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

What does the weighted average sale price mean in this Boston Scientific (BSX) Form 4?

The Form 4 notes that the $101.5531 figure is a weighted average sale price for shares sold in multiple transactions at prices ranging from $101.11 to $101.89 per share.